

Application No.: 09/809,638

2

Docket No.: 511582003500

**REMARKS**

The reproduction of an electronic mail message discussed in the previous response was inadvertently omitted from the filing. This response supplies that message.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 511582003500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 3, 2005

Respectfully submitted,

By 

James J. Mullen III, Ph.D.

Registration No.: 44,957

MORRISON &amp; FOERSTER LLP

12531 High Bluff Drive

Suite 100

San Diego, California 92130-2040

(858) 720-7940

sd-287649

AUG-31-2005 14:34

AGENSYS

310 820 7880 P.03/03

**Popp, Shane**

From: Mitchell, Steve  
Sent: Wednesday, January 03, 2001 1:43 PM  
To: Scientists  
Subject: 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is pasted. It is a PCR based pCR2.1/TA clone (prostate) with three point differences from the Japanese (colon) reported hypothetical sequence. Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

&gt;125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
CGATGACCTCGCTGTGGAGAGAAATCCTCTTGGAGTGGCTGCTGGGATGTGTTCTTGGTCTCTCTACCATGACCTGGGACCGATG
ATCTATTACTTTCTTTGCAAACTAGAACTCACTGGGCTTGAAGGTTTGTAGTATAGCATTTCTTCTCCAAATTTCTTAACTTACT
CCTTTCTGGAAATGGTTAAACAAGAGTGGATGCTAAACCTGCTGAGGATAATCACTATTGGCAGCATAGCCTCTTCCAGGCTCCA
AATGCCAAACTTGGACTGATGGTTCTTGGCTTGGGGTGTCTTCTCACTGATAGTGAAGCTGTGACTTGGTGGTGGGGAAGTCAT
TTGCAAGGTACCTCAGAAATTTGGGGATTCATTTAGGACAGATTGTTCTTGTGTCTACGCATATGGTATACTTCACTAAACCCAACT
CTGGAGTTATCAGATGTCCAACAAAGTGATACTGACATTAAAGTCCATAGCCACACTTGATCGTATTGGCAGAGATGGTGAATGCAG
TAAACCTGAAGAAAAGAAGACTGGTGAAGTAGCCACGGGGATGGCTTACCTGCACACATGGGCAGCTGCTGTGTCTGGTCTTTGGT
AGCCTTGTGTTCTCACCACCTGGGTTTGGGAGAGTCTCTCTTGTTCAGATGGGCAGTGAAGTGGGCATCCACATCCAGGGGC
AGATCTTAACCCATTGGAGGTGCACTACTGCTGTGCTTGGCAAGTGGATTGATGCTTCCATCTTGTGTGTGTCTGTGGTACTGG
TTGATCTGGTGGGTTACAGGAACAGCTTCACTGCGGGGCTCTTACCTGCACACATGGGCAGCTGCTGTGTCTGTGTGTCT
TCGCCATCTTACTGCATCCATGTGGGCCCAAACACTTGGACACCTTATTAACCTCAGGACAAACCCCTGGGAAAACCATGACCATTTG
CCATGATATTTATCTTCTAGAAATATTTCTGTGCTGGTGCACAGCTTTAAGTTTGTCCAGGAGGTGTCTACGCTAGAGAAAG
ATCAGATGTGCTTTTGGGGACAATGATGTTAATTATCGGGCTGAATATGCTATTTGGTCTAAGAAAACCTTGACTTGTCTTCTCAA
ACAAAAACAGTTCTAAAGTGCTTTTCAAGAAAGAGTGAAAAATACATGAAACTTTTCTGTGGCTGCTTGTGTGGGATTGTTGG
GATTAGGACTACGGCATAAAGCCTATGAGAGAAAACTGGGCAAGTGGCACCAACCAAGAGGTCTCTGCTGCCATCTGGCCTTTC
AGGTTTGGATATGACAAATGAAGGGTGGTCTAGTCTAGAAAGATCAGCTCACCTGCTCAATGAAACAGGTGCAGATTTCAAGCAATT
TTGGAGAGTGAATGCTTCTAAGCCCTATATGGGGAACAACTGACTTAACCATGTGGCTAGGGGAAAAGTTGGGTTTCTATACAGACTTT
GGTCCAAAGCAACAAGGTATCAGACTTGGGGATTATGGCTTTGTCAAGATACCAATTGTGAAATCTGAGCATCACCTTCTCCGTCA
CCAGAGGGCGAGATCGCACAGGCCATCAGATTGACCGTTAACATTTCCGGCAAGCTGGTGGATTGTGCTGTGACACACTTTGGGAA
CCACGAAGATGACCTCGACAGGAACTGCAGGCTATTGCTGTTTCAAACTACTGAAAAGTAGCTCTAATCAAGTGATATTTCTGGG
ATATATCACTTCAGCAGCTGGCTCCAGAGATTATCTACAGCTCACTGAACATGGCAATGTGAAGGATATCGACAGCACTGATCATGA
CAGATGGTGTGAATACATTATGTATCGAGGGCTGATCAGGTTGGGTTATGCAAGAATOTCCCATGCTGAAGTGAAGTATCAGAAAT
TCAGATGGCAAAATTTAGGATCCCTGATGACCCCACTAATTATAGAGACAACCAAGTGGTCAAGACCAAGAGAGATTTCTGA
GAAATTCATTTAATCCAGATTGGATCCTACAAAGAAGGACACAATTATGAAACAACCATCATTTCATATGAATACTCCCAAT
ACTTTTATGAAAC
```

&gt;125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
MTSLWREILLESLGCVSWSLYHDLGPMIYFFLQTLTGLEGFSIAFLSPHFLTTPFWKLVNKKWMLTLRIITIGSIABFOAPNAKLRLM
VLALGVSSSLVQAVTWVSGSHLQRYLRWGFILGOVLVLRWYTSLNPIWSYQMSNKVILTLSAIALDRIGTDGDCSKPEEKKKTGEVA
TGMASRPNWLLAGAAFGSLVFLTHWVFGVSVLSRWAVSGHPHGPDPNPFPGGAVLLCLASGLMLPSCWFRGTGLWVWVTGTASAA
GLLYLHTWAAVSGCVFAIFTASMWPTLGHUNSGTNPGKTMAMIFVLEIFFCAWCTAFKVPVGGVYARERSOVLGTMMLIIGLNM
FGPKNLDLLQTKNSSKVLFRKSEKYMKLFLWLLVGVGLLGLRHKAYERKLGKVAPTKEYSAAWPFRFGYDNEGWSSLSERSAHL
NETGADFTILESADSKPYMGNDLTMWLGEKLGFTYDFGPSTRYHTWGMALSRYPIVKSEHLLPSPEGEIAPATLTVNISGKLVDFV
THFGNHEDDLDRKLQAIASVSKLLKSSSNQVIFLGYTTSAPGSRDYLQLTEHGNVKKIDSDTDHWRWCEYIMYRGRLGLYARISHAELSDSEI
QMAKFRIPDOPTNYRDNQKVVDHREVSEKHFNPRFGSYKEGHNYENNHHFHMNTPKYFL
```

Steve Chappell Mitchell  
Associate Scientist  
UroGenesys  
1701 Colorado Avenue  
Santa Monica, CA 90404  
Tel (310)820-8029 x231  
Fax (310)820-8489  
Email smitchell@urogenesys.com  
Url www.urogenesys.com

**BEST AVAILABLE COPY**